Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.70 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.70 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL1B | P01584 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25475645 | 0.90 | DDB1 (0.74) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL14218469 | 0.90 | DDB1 (0.74) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18945872 | 0.88 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18904277 | 0.88 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283241 | 0.88 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2603174 | 0.88 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL284302 | 0.88 | DDB1 (0.74) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24113880 | 0.87 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| Hydrochloric Acid SCHEMBL284301 | 0.87 | DDB1 (0.72) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26317880 | 0.87 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | DDB1 480/4885CRBN 330/4885IKZF3 1741/4885 |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | MAP2K2, MAP2K1, MAP2K7 | DDB1 995/4885CRBN 1094/4885IKZF3 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.